Patents by Inventor Stephanos Ioannidis

Stephanos Ioannidis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors
    Patent number: 11795171
    Abstract: The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where R1, R2, R3, R4, R5, R5?, R6, X1, X2, m, and n are described herein.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: October 24, 2023
    Assignee: Valo Health, Inc.
    Inventors: Stephanos Ioannidis, Adam Charles Talbot, Bruce Follows, Alexandre Joseph Buckmelter, Minghua Wang, Ann-Marie Campbell
  • Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
    Patent number: 11739071
    Abstract: The present disclosure relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where R1, R2, R3, R4, R4?, X1, Y1, Y2, Y3, Y4, n, and m are described herein.
    Type: Grant
    Filed: November 12, 2020
    Date of Patent: August 29, 2023
    Assignee: Valo Health, Inc.
    Inventors: Stephanos Ioannidis, Adam Charles Talbot, Bruce Follows, Alexandre Joseph Buckmelter, Minghua Wang, Ann-Marie Campbell, David R. Lancia, Jr.
  • PPARg MODULATORS AND METHODS OF USE
    Publication number: 20230062861
    Abstract: Disclosed herein are novel compounds of Formula (1) and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing the same, and methods of using the same.
    Type: Application
    Filed: November 8, 2021
    Publication date: March 2, 2023
    Inventors: Sudeep PRAJAPATI, Hyelee LEE, Stephanos IOANNIDIS, Kiyoyuki OMOTO, Alan ROLFE, Xiang LIU, Megan SHEEHAN, Paul DRANSFIELD, Andrew COOK
  • Carboxamides as ubiquitin-specific protease inhibitors
    Patent number: 11524966
    Abstract: The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25 can be useful in the treatment of cancers, among other ailments.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: December 13, 2022
    Assignee: Valo Health, Inc.
    Inventors: David J. Guerin, Pui Yee Ng, Zhongguo Wang, Tatiana Shelekhin, Justin Caravella, Hongbin Li, Stephanos Ioannidis, Mary-Margaret Zablocki
  • PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS
    Publication number: 20220281869
    Abstract: The application relates to inhibitors of USP1 useful in the treatment of cancers, and other USP1 associated diseases and disorders, having the Formula: where R1, R2, R3, R3?, R4, R5, X1, X2, X3, X4, and n are described herein.
    Type: Application
    Filed: September 30, 2021
    Publication date: September 8, 2022
    Inventors: Alexandre Joseph Buckmelter, Stephanos Ioannidis, Bruce Follows, Gary Gustafson, Minghua Wang, Justin Andrew Caravella, Zhongguo Wang, Edward L. Fritzen, Jian Lin
  • INHIBITING USP19
    Publication number: 20220213059
    Abstract: The present disclosure is directed to compounds of formulas (I)-(VI), which are useful as modulators of USP19. The compounds are further useful in the inhibition of USP19 and the treatment of diseases or disorders associated with the inhibition of USP19. For instance, the disclosure is concerned with compounds and compositions for inhibition of USP19 and methods of treating diseases associated with the inhibition of USP19 (e.g., Parkinson's disease, Ewing sarcoma, and other metabolic diseases including muscle wasting and diabetes).
    Type: Application
    Filed: May 6, 2020
    Publication date: July 7, 2022
    Inventors: Lawrence MARCIN, Bingsong HAN, Stephanos IOANNIDIS, Katherine KAYSER-BRICKER, Cuixian LIU, Adam TALBOT
  • INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30
    Publication number: 20220185806
    Abstract: The present disclosure relates to chemical entities useful as inhibitors of Ubiquitin Specific Peptidase 30 (USP30), pharmaceutical compositions comprising the chemical entities, and methods of using the chemical entities. The chemical entities as disclosed herein can be useful in the treatment of a disease, disorder, or condition involving mitochondrial dysfunction, including neurodegenerative diseases, motor neuron diseases, metabolic disorders, and cancers, among other ailments.
    Type: Application
    Filed: December 21, 2021
    Publication date: June 16, 2022
    Inventors: Justin Caravella, Bingsong Han, Cuixian Liu, Stephanos Ioannidis, Alexandre Joseph Buckmelter, David James Richard, Matthew W. Martin, Steven Mischke, Scot Mente
  • Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors
    Patent number: 11325917
    Abstract: The disclosure relates to inhibitors of USP28 and/or USP25 useful in the treatment of cancers, inflammation, autoimmune diseases, and infectious diseases, having the Formula: (I), where R1, R2, R3, R4, R4?, R5, R6, X, and n are described herein.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: May 10, 2022
    Assignee: VALO HEALTH, INC.
    Inventors: David Joseph Guerin, Kenneth W. Bair, Justin A. Caravella, Stephanos Ioannidis, David R. Lancia, Jr., Hongbin Li, Steven Mischke, Pui Yee Ng, David Richard, Shawn E. R. Schiller, Tatiana Shelekhin, Zhongguo Wang
  • Inhibiting ubiquitin specific peptidase 30
    Patent number: 11247987
    Abstract: The present disclosure relates to chemical entities useful as inhibitors of Ubiquitin Specific Protease 30 (USP30), pharmaceutical compositions comprising the chemical entities, and methods of using the chemical entities. The chemical entities as disclosed herein can be useful in the treatment of a disease, disorder, or condition involving mitochondrial dysfunction, including neurodegenerative diseases, motor neuron diseases, metabolic disorders, and cancers, among other ailments. Chemical entities disclosed herein include compounds of Formula (II): wherein A, R2, R3, R4, Ra, Rc, Rd, Re, Rf, and m are defined herein.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: February 15, 2022
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Justin Caravella, Bingsong Han, Cuixian Liu, Stephanos Ioannidis, Alexandre Joseph Buckmelter, David James Richard, Matthew W. Martin, Steven Mischke, Scot Mente
  • PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS
    Publication number: 20220033403
    Abstract: The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where R1, R2, R3, R4, R5, R5?, R6, X1, X2, m, and n are described herein.
    Type: Application
    Filed: April 14, 2021
    Publication date: February 3, 2022
    Inventors: Stephanos Ioannidis, Adam Charles Talbot, Bruce Follows, Alexandre Joseph Buckmelter, Minghua Wang, Ann-Marie Campbell
  • Purinones as ubiquitin-specific protease 1 inhibitors
    Patent number: 11161848
    Abstract: The application relates to inhibitors of USP1 useful in the treatment of cancers, and other USP1 associated diseases and disorders, having the Formula: where R1, R2, R3, R3?, R4, R5, X1, X2, X3, X4, and n are described herein.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: November 2, 2021
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Alexandre Joseph Buckmelter, Stephanos Ioannidis, Bruce Follows, Gary Gustafson, Minghua Wang, Justin A. Caravella, Zhongguo Wang, Edward L. Fritzen, Jian Lin
  • PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS
    Publication number: 20210332052
    Abstract: The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where m, n, X1, X2, R1-R5, R5? and R6 are described herein.
    Type: Application
    Filed: February 26, 2021
    Publication date: October 28, 2021
    Inventors: Stephanos Ioannidis, Adam Charles Talbot, Bruce Follows, Alexandre Joseph Buckmelter, Minghua Wang, Ann-Marie Campbell, Darby Rye Schmidt, David Joseph Guerin, Justin Andrew Caravella, R. Bruce Diebold, Anna Ericsson, David R. Lancia, JR.
  • CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS
    Publication number: 20210323975
    Abstract: The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25 can be useful in the treatment of cancers, among other ailments.
    Type: Application
    Filed: August 8, 2019
    Publication date: October 21, 2021
    Inventors: David J. GUERIN, Pui Yee NG, Zhongguo WANG, Tatiana SHELEKHIN, Justin CARAVELLA, Mary-Margaret ZABLOCKI, Jennifer R. DOWNING, Hongbin LI, Stephanos IOANNIDIS
  • ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS
    Publication number: 20210323978
    Abstract: The disclosure relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where R1, R2, R3, R4, R5, R5?, X1, X2, X3, n, and m are described herein.
    Type: Application
    Filed: February 18, 2021
    Publication date: October 21, 2021
    Inventors: Stephanos Ioannidis, Adam Charles Talbot, Bruce Follows, Alexandre Joseph Bckmelter, Minghua Wang, Ann-Marie Campbell
  • THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS
    Publication number: 20210292337
    Abstract: The disclosure relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where R1, R2, R3, R5, R5?, X1, X2, n, and m are described herein.
    Type: Application
    Filed: January 28, 2021
    Publication date: September 23, 2021
    Inventors: Stephanos Ioannidis, Adam Charles Talbot, Bruce Follows, Alexandre Joseph Buckmelter, Minghua Wang, Ann-Marie Campbell, David R. Lancia, JR.
  • QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS
    Publication number: 20210130321
    Abstract: The present disclosure relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where R1, R2, R3, R4, R4?, X1, Y1, Y2, Y3, Y4, n, and m are described herein.
    Type: Application
    Filed: November 12, 2020
    Publication date: May 6, 2021
    Inventors: Stephanos Ioannidis, Adam Charles Talbot, Bruce Follows, Alexandre Joseph Buckmelter, Minghua Wang, Ann-Marie Campbell, David R. Lancia, JR.
  • Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors
    Patent number: 10981915
    Abstract: The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where R1, R2, R3, R4, R5, R5?, R6, X1, X2, m, and n are described herein.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: April 20, 2021
    Assignee: Valo Early Discovery, Inc.
    Inventors: Stephanos Ioannidis, Adam Charles Talbot, Bruce Follows, Alexandre Joseph Buckmelter, Minghua Wang, Ann-Marie Campbell
  • Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors
    Patent number: 10934299
    Abstract: The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where m, n, X1, X2, R1-R5, R5? and R6 are described herein.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: March 2, 2021
    Assignee: Valo Early Discovery, Inc.
    Inventors: Stephanos Ioannidis, Adam Charles Talbot, Bruce Follows, Alexandre Joseph Buckmelter, Minghua Wang, Ann-Marie Campbell, Darby Rye Schmidt, David Joseph Guerin, Justin Andrew Caravella, R. Bruce Diebold, Anna Ericsson, David R. Lancia, Jr.
  • Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
    Patent number: 10927130
    Abstract: The disclosure relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where R1, R2, R3, R4, R5, R5?, X1, X2, X3, n, and m are described herein.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: February 23, 2021
    Assignee: Valo Early Discovery, Inc.
    Inventors: Stephanos Ioannidis, Adam Charles Talbot, Bruce Follows, Alexandre Joseph Buckmelter, Minghua Wang, Ann-Marie Campbell
  • THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS
    Publication number: 20210047343
    Abstract: The disclosure relates to inhibitors of USP28 and/or USP25 useful in the treatment of cancers, inflammation, autoimmune diseases, and infectious diseases, having the Formula: (I), where R1, R2, R3, R4, R4?, R5, R6, X, and n are described herein.
    Type: Application
    Filed: August 26, 2020
    Publication date: February 18, 2021
    Inventors: David Joseph Guerin, Kenneth W. Bair, Justin A. Caravella, Stephanos Ioannidis, David R. Lancia, JR., Hongbin Li, Steven Mischke, Pui Yee Ng, David Richard, Shawn E.R. Schiller, Tatiana Shelekhin, Zhongguo Wang